Viewing Study NCT03884192

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:37 PM
Ignite Modification Date: 2026-02-02 @ 6:22 PM
Study NCT ID: NCT03884192
Status: UNKNOWN
Last Update Posted: 2019-03-21
First Post: 2019-01-11
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC
Sponsor: Shandong Cancer Hospital and Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Non-Small Cell Lung View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Locally advanced View
None Stage III Non-Small Cell Lung Cancer View
None Unresectable Non-Small Cell Lung Cancer View
None Concurrent Chemoradiation View
None Immune-mediated cancer therapy View
None PD-1 View
None Sintilimab View
None IBI308 View